By targeting overactive effector T cells, including Th1 and Th17 cells, as well as proinflammatory cytokines such as interferon interferon-gamma (IFN-γ) and IL-17, metformin shows potential in reducing inflammation in Systemic Lupus Erythematosus (SLE) (Tan et al., 2019). Here, IL17A is linked to systemic lupus erythematosus.